StockData
Castle Biosciences Inc logo

Castle Biosciences Inc (CSTL) stock

CSTLNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 11/304% below fair value
$32.98+0.23 (+0.70%)

Close on Nov 17, 2026Market cap $1.01BP/E –Yield 0.00%

Castle Biosciences total assets

Total assets on the balance sheet at the end of each period.

Castle Biosciences's total assets was $579.41M at Sep 30, 2026. For fiscal 2025 it was $578.56M, up 8.9% from the year before. The highest annual figure on record is $578.56M in fiscal 2025.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$578.56M+8.9%
FY2024Dec 31, 2024$531.24M+17.2%
FY2023Dec 31, 2023$453.34M+1.3%
FY2022Dec 31, 2022$447.33M-3.3%
FY2021Dec 31, 2021$462.57M+5.3%
FY2020Dec 31, 2020$439.33M+266.9%
FY2019Dec 31, 2019$119.75M+434.5%
FY2018Dec 31, 2018$22.41M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$579.41M+3.0%
Q2 FY2026Jun 30, 2026$561.18M+3.0%
Q1 FY2026Mar 31, 2026$547.81M+9.2%
Q4 FY2025Dec 31, 2025$578.56M+8.9%
Q3 FY2025Sep 30, 2025$562.79M+9.4%
Q2 FY2025Jun 30, 2025$544.73M+11.8%
Q1 FY2025Mar 31, 2025$501.72M+9.4%
Q4 FY2024Dec 31, 2024$531.24M+17.2%
Q3 FY2024Sep 30, 2024$514.57M+18.0%
Q2 FY2024Jun 30, 2024$487.31M+14.6%
Q1 FY2024Mar 31, 2024$458.51M+7.4%
Q4 FY2023Dec 31, 2023$453.34M+1.3%
Q3 FY2023Sep 30, 2023$436.02M-4.8%
Q2 FY2023Jun 30, 2023$425.40M-7.2%
Q1 FY2023Mar 31, 2023$426.89M-3.9%
Q4 FY2022Dec 31, 2022$447.33M-3.3%
Q3 FY2022Sep 30, 2022$457.81M+5.6%
Q2 FY2022Jun 30, 2022$458.38M+5.2%
Q1 FY2022Mar 31, 2022$444.43M+1.6%
Q4 FY2021Dec 31, 2021$462.57M+5.3%
Q3 FY2021Sep 30, 2021$433.69M+106.1%
Q2 FY2021Jun 30, 2021$435.53M+116.1%
Q1 FY2021Mar 31, 2021$437.33M+263.7%
Q4 FY2020Dec 31, 2020$439.33M+266.9%
Q3 FY2020Sep 30, 2020$210.39M+85.9%
Q2 FY2020Jun 30, 2020$201.55M+504.4%
Q1 FY2020Mar 31, 2020$120.26M+436.7%
Q4 FY2019Dec 31, 2019$119.75M–
Q3 FY2019Sep 30, 2019$113.20M–
Q2 FY2019Jun 30, 2019$33.35M–
Q4 FY2018Dec 31, 2018$22.41M–

More Castle Biosciences figures

See a number that looks wrong?